Shares Of Micro Cap Biotech Surge After Breakthrough FDA Designation

Sponsored:

Monday, July 21, 2025

Alzheimer’s disease impacts more than 6 million Americans and remains a significant public health challenge with few effective treatment options. Fortunately, a new development announced this morning by a micro-cap biotech company could one day offer another promising option to help those affected by this devastating condition.

Shares of ProMIS Neurosciences Inc. (Nasdaq: PMN) are surging after the company announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its lead drug candidate, PMN310, aimed at treating Alzheimer’s disease. The company, which focuses on developing antibody-based therapies for neurodegenerative disorders such as Alzheimer’s, ALS, and Parkinson’s, sees this recognition as an important milestone. The FDA’s Fast Track program is designed to speed up the development and review of treatments for serious conditions that address unmet medical needs, providing increased interaction with the agency and the possibility of a quicker approval process.

Currently, PMN310 is being studied in the PRECISE-AD Phase 1b clinical trial, which is enrolling patients with early-stage Alzheimer’s disease. This study is focused on assessing the safety and tolerability of PMN310, as well as its pharmacokinetics and effect on biomarkers associated with Alzheimer’s. ProMIS expects to share interim results, including six-month biomarker and safety data, in the second quarter of 2026, with final outcomes anticipated by the end of that year.

According to the company, PMN310 stands out for its ability to specifically target toxic oligomers of amyloid-beta, avoiding plaque and potentially minimizing side effects like ARIA that are seen with other treatments. By focusing on the most harmful forms of amyloid and avoiding off-target interactions, PMN310 may offer a safer and more effective alternative to existing amyloid-targeted therapies.

Shares of PMN are up 170.39% at $1.19 per share in late-morning trading as investors pile in to the stock after today’s important corporate development.

Sponsored: